Vidofludimus calcium for the treatment of multiple sclerosis: development rationale, mechanism of action, and early trial data.
Ondrus M, Fox RJ, Peelen E, Fonseca J, Sciacca V, Sanchez-Gomez I, Arend J, Herrmann A, Samcova M, Gege C, Havrylova L, Kohlhof H, Tardio J, Vitt D, Muehler A
Vidofludimus calcium is an oral medication that activates the Nurr1 protein and inhibits inflammation, showing promise in reducing brain lesions for multiple sclerosis patients. While it targets the same protein family as NR4A2, it is currently being tested only for autoimmune neurological conditions, not developmental disorders.
- Vidofludimus calcium directly activates Nurr1, the protein encoded by the NR4A2 gene.
- Phase 2 trials show reduced brain lesions in multiple sclerosis patients.
- The drug targets neuroinflammation and neurodegeneration pathways.
- It is currently in Phase 3 trials for multiple sclerosis only.
- No clinical data exists for its use in NR4A2-related developmental disorders.
Development of a Brain-Penetrant Nurr1 Agonist Tool.
Vietor J, Stiller T, Gege C, Saeb W, López-García Ú, Kohlhof H, Vitt D, Merk D
Researchers developed a new brain-penetrant drug that activates the Nurr1 protein to study its potential effects in the central nervous system. This compound is a chemical tool designed for laboratory research rather than a tested treatment for patients.
- The drug activates Nurr1, a protein linked to neuroprotection and NR4A2-related syndromes.
- It crosses the blood-brain barrier effectively for central nervous system studies.
- This is preclinical research using chemical tools, not human clinical data.
- No evidence exists yet that this specific compound treats symptoms in people.
Genetic Variants and Clinical Characteristics of Young-Onset Parkinson's Disease in the Hakka Population of Western Fujian.
Pan LY, Guo F, Zheng C, Hu XH, Chen YG, Lin RR
This study identifies NR4A2 as a susceptibility gene in young-onset Parkinson's disease within a specific ethnic population. It provides human genetic evidence linking NR4A2 variants to dopaminergic neuron dysfunction, which is relevant to the underlying biology of NR4A2-related syndromes.
- NR4A2 variants were found in patients with young-onset Parkinson's disease.
- The study confirms human genetic links between NR4A2 and dopaminergic pathways.
- Findings support the role of NR4A2 in neurodevelopmental and movement disorders.
Dysregulation of astrocytic DNAJC6 contributes to sporadic Parkinson's disease pathogenesis.
Darsono WHW, Hwang Y, Valencia E, Gunawan LT, Hyeon SJ, Ryu H, Stein TD, Chang MY, Wulansari N, Lee SH
This study identifies that reduced levels of the protein DNAJC6 in astrocytes drive inflammation and neurodegeneration in sporadic Parkinson's disease. Researchers demonstrate that restoring DNAJC6 levels using gene therapy alleviates symptoms in a mouse model of the disease.
- DNAJC6 is downregulated in postmortem brain tissue from patients with late-onset Parkinson's disease.
- Loss of DNAJC6 in astrocytes impairs cellular cleanup and promotes inflammation.
- Gene therapy restoring DNAJC6 improves behavior and pathology in a mouse model.
- The mechanism involves reduced transcription by NURR1 and FOXA2 factors.
Valsartan promotes neuroprotection in Parkinson's disease via epigenetic modulation and activation of the ASCL1/Nurr1 pathway.
Gowied HG, El-Mezayen NS, Afify EA
This study shows that valsartan protects dopamine-producing neurons and improves motor function in rats with Parkinson's disease by activating the Nurr1 pathway. The drug also modifies epigenetic markers to reduce neuronal damage, but these findings are based entirely on animal models.
- Valsartan improved motor skills and protected neurons in a rat model of Parkinson's disease.
- The drug activated Nurr1, a transcription factor related to NR4A2, to restore dopamine neuron health.
- Blocking Nurr1 reduced the drug's benefits, confirming its central role in neuroprotection.
- Results are preclinical; no human clinical trials or safety data for children exist yet.
The genetic architecture of Parkinson's disease in Mexico: a systematic review.
Arias-Carrión O, Romero-Gutiérrez E, Castellanos-Juárez FX, Sandoval-Carrillo AA, Salas-Pacheco JM
This review identifies NR4A2 as a recurrent genetic locus associated with Parkinson's disease in Mexican populations, distinguishing specific haplotypes that either increase risk or offer protection. It confirms that NR4A2 variants play a role in dopaminergic signaling pathways relevant to neurodevelopmental and parkinsonian conditions.
- NR4A2 is one of eight loci recurrently associated with Parkinson's disease in Mexican cohorts.
- Specific NR4A2 haplotypes are identified as either protective (H1) or risk-increasing (H2).
- The study includes human genetic data, providing direct evidence on NR4A2 variant effects.
- Findings converge on dopaminergic signaling and mitochondrial quality control pathways.
Generating graftable dopaminergic neurons by NR4A2 activation and exploring associated lncRNA signatures.
Malekmohammad L, Esfahani NMJ, Momeni Z, Esmaeili F, Khademizadeh M, Farhadieh ME, Karimi F, Keimasi M, Soleimani-Delfan A
Activating the NR4A2 gene in stem cells produces dopaminergic neurons that survive transplantation and increase dopamine levels in a rat model of Parkinson's disease. This study demonstrates a potential method for generating graftable neural cells but relies entirely on animal models and cell cultures.
- NR4A2 activation drives stem cells to become dopaminergic neurons suitable for transplantation.
- Transplanted cells survive in rat brains and elevate dopamine concentrations compared to controls.
- Specific long non-coding RNAs increase alongside dopaminergic markers after cell grafting.
- The research uses P19 stem cells and Parkinson's rat models, not human patients.
The Interplay Between Nurr1 and Mitochondrial Biogenesis: Implications for Neurodegenerative Therapy.
Kaur S, Mannan A, Singh TG
This review explains how the NR4A2 protein supports mitochondrial health and protects dopamine-producing neurons from oxidative stress, which is relevant to understanding the cellular mechanisms underlying neurodegeneration. It highlights that maintaining proper NR4A2 function helps sustain neuronal survival by regulating energy production and reducing cellular damage.
- NR4A2 regulates genes essential for mitochondrial biogenesis and dopamine synthesis.
- The protein interacts with PGC-1α to maintain healthy mitochondrial activity.
- Post-translational modifications enhance NR4A2's ability to reduce oxidative stress.
- Dysregulated NR4A2 leads to decreased mitochondrial function and neuronal loss.
- Restoring NR4A2-mediated mitochondrial support is a potential therapeutic strategy.
Epigenome-wide analysis identifies DNA methylation signatures associated with the infant pupillary light reflex, a candidate intermediate phenotype for autism.
Fish LA, Gliga T, Gui A, Ali JB, Mason L, Johnson MH, Charman T, Falck-Ytter T, Jones EJH, Kandaswamy R, Happé F, Wong CCY
This study links DNA methylation patterns to variations in the infant pupillary light reflex, a trait associated with autism risk. It identifies NR4A2 as one of several genes whose methylation status correlates with these early neurodevelopmental differences.
- The study analyzes DNA methylation in infants linked to autism likelihood.
- It measures the pupillary light reflex at 9, 14, and 24 months.
- NR4A2 is identified among genes associated with reflex variations.
- Findings suggest epigenetic factors influence early neural circuitry development.
Targeting Nurr1 With Amodiaquine Preserves Dendritic Spines and Cognitive Function After Chronic Cerebral Hypoperfusion.
Zeng X, Xie X, Zhang J, Jia J, Huang L
Treating rats with the drug amodiaquine, which activates Nurr1, improves memory and protects brain cells after chronic low blood flow. This preclinical study shows that boosting Nurr1 activity can preserve cognitive function and brain structure in an animal model of vascular damage.
- Amodiaquine acts as a Nurr1 agonist to improve cognitive outcomes in rats.
- Treatment reverses white matter loss and protects hippocampal dendritic spines.
- Memory benefits persist for weeks after the two-week treatment course ends.
- The study uses a rat model of chronic cerebral hypoperfusion, not human patients.
Dual Nurr1/RXR agonism of valerenic acid and synthetic mimetics enables dimer-selective Nurr1 modulation.
Scholz K, López-García Ú, Busch R, Marschner JA, Merk D
Valerenic acid and its synthetic mimics selectively activate the Nurr1/RXR heterodimer while destabilizing the Nurr1 homodimer in neuronal cells. This selective activation enhances only a subset of Nurr1-induced genes, offering a potential strategy to modulate Nurr1 function with greater specificity.
- Valerenic acid acts as a dual agonist for both Nurr1 and RXR receptors.
- Dual activation selectively stabilizes the Nurr1/RXR heterodimer over the homodimer.
- Selective heterodimer activation modulates only a subset of target genes in neurons.
- This approach provides proof-of-concept for dimer-selective Nurr1 modulation.
Genetic and Environmental Risk Factors for Autism Spectrum Disorder in Saudi Arabia: A Systematic Review.
Hamed NF, Alqahtani AM, Alshaibani F, Elsharif SM, Alamri SAS, Serhan A
This systematic review identifies NR4A2 loss-of-function variants as a genetic risk factor for autism spectrum disorder in the Saudi population. It highlights that regional factors like consanguinity and prenatal environmental exposures contribute to the condition's complexity.
- NR4A2 loss-of-function variants associate with autism risk in this specific cohort.
- Consanguinity amplifies the burden of recessive genetic variants in the population.
- Prenatal phthalate exposure and maternal stress are key environmental risk factors.
- The study synthesizes 13 regional studies on ASD etiology.
Early α-Synuclein Pathology Induces Neuroinflammation and Decreases Topoisomerase IIβ Expression in A53T Mice.
Yeman-Kıyak B, Yurdakul T, Selim A, Elibol B, Avşar T, Neğiş Y, Sürmen MG, Şeyhali-Abutayeh R, Akbayır R, Eren MC, Öz P, Çevreli B, Işık S
This mouse study links early Parkinson's-related protein buildup to increased brain inflammation and reduced levels of Nurr1, the protein affected by NR4A2 mutations. It suggests that targeting inflammation or DNA topology might help preserve Nurr1 function in early disease stages.
- Transgenic mice with Parkinson-linked alpha-synuclein show early cognitive and motor decline.
- Brain inflammation markers rise significantly even in the earliest disease stage tested.
- Nurr1 protein levels drop sharply in young transgenic mice alongside DNA repair enzyme loss.
- The study proposes that reducing inflammation could protect Nurr1 expression during early pathology.
Nurr1 deficiency impairs autophagy-lysosomal function through GBA-dependent transcriptional regulation in Parkinson's disease pathogenesis.
Cheng C, Yang H, Tian L, Ni Y, Jia C, Le W, Wang Q
Nurr1 deficiency disrupts lysosomal function and autophagy in dopaminergic neurons by downregulating the GBA gene, a mechanism linked to Parkinson's disease pathology. This study identifies a specific molecular pathway where loss of Nurr1 leads to impaired cellular waste clearance through GBA-dependent transcriptional regulation.
- Nurr1 deficiency causes lysosomal alkalization and impairs autophagy-lysosomal pathway function.
- Nurr1 directly regulates GBA expression, which controls key lysosomal protein levels.
- Overexpressing GBA attenuates the lysosomal dysfunction caused by Nurr1 loss.
- This mechanism links Nurr1 biology to Parkinson's disease pathogenesis via cellular clearance defects.
Adult human subventricular zone microglia promote a pro-neurogenic niche for neuronal progenitors in Parkinson's disease.
Pecoraro S, Verkerke M, Sluijs JA, van Het Hof B, van der Pol SMA, van Strien ME, van der Kant R, de Vries C, de Vries HE, van de Berg WDJ, Hol EM, Donega V
Microglia from the brains of people with Parkinson's disease create an environment that stimulates the growth and differentiation of new neurons. This pro-neurogenic effect relies on NR4A2, which helps keep these immune cells in an anti-inflammatory state.
- Parkinson's disease microglia promote neuronal progenitor proliferation and differentiation.
- NR4A2 drives this anti-inflammatory, pro-neurogenic microglia phenotype.
- The study uses post-mortem human brain tissue and iPSC-derived cells.
- Findings suggest targeting NR4A2 in microglia could aid neurorepair.
Molecular Screening Reveals De Novo Loss-of-Function NR4A2 Variants in Saudi Children with Autism Spectrum Disorders: A Single-Center Study.
Alharbi NM, Baaboud WF, Shawky H, Alrofaidi AA, Farsi RM, Algothmi KM, Hassoubah SA, Basingab FS, Azhari SA, Alharbi MG, Yahya R, Alhazmi S
This study identifies de novo loss-of-function variants in the NR4A2 gene in a subset of children with autism spectrum disorder, confirming that these genetic changes contribute to neurodevelopmental conditions. The findings reinforce the link between NR4A2 mutations and developmental delays, providing further evidence for the genetic basis of this syndrome.
- Researchers screened 338 children with autism for NR4A2 gene variants using exome sequencing.
- Ten de novo variants were found in eight unrelated families, including loss-of-function mutations.
- The study confirms NR4A2 haploinsufficiency contributes to autism and neurodevelopmental delays.
- Some identified variants were recurrent, suggesting a significant role in this population's etiology.
Retinoid X Receptor as a Therapeutic Target to Treat Neurological Disorders Associated with α-Synucleinopathy.
Zhylkibayev A, Starr CR, Hossain MI, Kumar S, Andrabi SA, Grant MB, Atigadda VR, Gorbatyuk MS, Gorbatyuk OS
Overexpressing the RXRα receptor in a mouse model of Parkinson's disease protects dopamine neurons, reduces inflammation, and restores levels of NURR1. This suggests that targeting RXR could theoretically help preserve dopaminergic function in conditions involving alpha-synuclein pathology.
- RXRα overexpression preserves dopamine-producing neurons in mice with Parkinson-like symptoms.
- Treatment reduces neuroinflammation and alpha-synuclein accumulation in the brain.
- RXRα upregulation increases NURR1 protein levels, which are often low in this disease model.
- This is a preclinical study using mouse models, not human patients.
Transcriptional evidence of reduced BDNF trophic capacity in the post-mortem human midbrain of schizophrenia cases with high inflammation.
Chandra JJ, Zhu Y, Petty A, Kostoglou Y, Haynes WX, Webster MJ, Weickert CS
This study finds that schizophrenia patients with high brain inflammation have lower levels of NURR1 and BDNF, which are critical for dopamine neuron health. These molecular changes suggest that inflammation may damage the support systems for dopamine neurons in the human midbrain.
- Schizophrenia cases with high inflammation show reduced NURR1 and BDNF mRNA levels.
- Inflammation exacerbates the decrease in trophic support factors for dopamine neurons.
- Antipsychotic medication does not explain these specific molecular changes.
- The study confirms human post-mortem evidence of dopaminergic vulnerability.
The selenocysteine-containing protein SELENOT maintains dopamine signaling in the midbrain to protect mice from hyperactivity disorder.
Guo Q, Li ZF, Hu DY, Li PJ, Wu KN, Fan HH, Deng J, Wu HM, Zhang X, Zhu JH
SELENOT deficiency in mouse dopaminergic neurons causes ADHD-like hyperactivity by disrupting dopamine transporter levels through NURR1 regulation. Treatment with standard ADHD medications reverses these behavioral symptoms in the affected mice.
- SELENOT loss in mouse dopamine neurons triggers hyperactivity and impulsivity.
- Mechanism involves SELENOT regulating NURR1 to control dopamine transporter expression.
- ADHD drugs like amphetamine reverse hyperactivity in these deficient mice.
Genetic variants associated with idiopathic Parkinson's disease in Latin America: A systematic review.
Duarte-Zambrano F, Alfonso-Cedeño DF, Barrero JA, Rodríguez-Vanegas LA, Moreno-Cárdenas V, Olarte-Díaz A, Arboleda G, Arboleda H
This systematic review identifies genetic variants linked to Parkinson's disease in Latin American populations, including specific insertions and deletions (INDELs) within the NR4A2 gene. The findings confirm that NR4A2 variations contribute to Parkinson's risk, providing human genetic evidence relevant to understanding this gene's role in dopaminergic health.
- The review analyzes nineteen case-control studies from Latin America.
- It identifies specific NR4A2 INDELs associated with Parkinson's disease risk.
- NR4A2 variants show mixed effects on disease susceptibility.
- Findings overlap with European genetic data but highlight population-specific markers.
- Human genetic sequencing of NR4A2 provides direct evidence for its clinical impact.
Retinoid X Receptor as a Therapeutic Target to Treat Neurological Disorders Associated with α -Synucleinopathy.
Zhylkibayev A, Starr CR, Hossain MI, Barodia SK, Andrabi SA, Grant MB, Atigadda VR, Gorbatyuk MS, Gorbatyuk OS
Overexpressing the RXRα receptor in a mouse model of Parkinson's disease protects dopamine neurons, reduces neuroinflammation, and prevents the accumulation of toxic alpha-synuclein proteins. This protection occurs partly by restoring levels of NURR1 (NR4A2) and PPARα, suggesting that activating this pathway could be a viable therapeutic strategy for neurodegenerative conditions.
- RXRα activation preserves dopamine neurons in mice with Parkinson-like pathology.
- Treatment reduces alpha-synuclein aggregates and markers of brain inflammation.
- RXRα overexpression restores NURR1 (NR4A2) levels, which are often diminished in disease.
- The study uses a mouse model, not human clinical data.
Clinical and genetic findings in autism spectrum disorders analyzed using exome sequencing.
Blázquez A, Rodriguez-Revenga L, Alvarez-Mora MI, Calvo R
Exome sequencing identified a pathogenic variant in the NR4A2 gene in one patient with autism spectrum disorder and intellectual disability. This finding confirms that NR4A2 mutations can occur in individuals diagnosed with ASD, linking the gene to this specific clinical presentation.
- The study sequenced exomes from 20 subjects with autism spectrum disorder.
- Eighty percent of participants had co-occurring intellectual disability.
- A pathogenic NR4A2 variant was found in one patient.
- Patients with positive findings often showed dysmorphic features and hypotonia.
BRF110, an Orally Active Nurr1-RXRα-Selective Rexinoid, Enhances BDNF Expression without Elevating Triglycerides.
Asvos X, El Mubarak MA, Karampelas T, Rampias T, Tamvakopoulos C, Sivolapenko GB, Papakyriakou A, Topouzis S, Vassilatis DK, Fokas D
Researchers developed a new oral drug, BRF110, that selectively targets the Nurr1-RXRα pathway to boost brain-derived neurotrophic factor (BDNF) and protect dopamine neurons. This compound avoids the high triglyceride side effects seen with existing drugs in this class while effectively crossing into the brain.
- BRF110 selectively activates Nurr1-RXRα, a pathway relevant to NR4A2 function.
- The drug increases BDNF expression and protects dopamine cells in mice.
- It crosses the blood-brain barrier effectively for potential brain treatment.
- Unlike older drugs, it does not raise triglyceride levels in vivo.
A Nurr1 Agonist Derived from the Natural Ligand DHI Induces Neuroprotective Gene Expression.
Egner M, Busch R, López-García Ú, Lewandowski M, Höfner G, Wein T, Marschner JA, Merk D
Researchers developed a potent, selective drug that activates the Nurr1 protein to boost neuroprotective gene expression in neuronal cells. This compound serves as a chemical tool to study how activating Nurr1 might protect neurons from degeneration.
- The new drug activates Nurr1 with high affinity and selectivity.
- It increases expression of neuroprotective genes like BDNF in cell cultures.
- The compound shows low toxicity and favorable chemical properties.
- This is preclinical research using neuronal cells, not human trials.
Implications of prenatal exposure to hyperandrogen for hippocampal neurodevelopment and autism-like behavior in offspring.
Qiao D, Mu C, Chen H, Wen D, Wang Z, Zhang B, Guo F, Wang C, Zhang R, Wang C, Cui H, Li S
Prenatal exposure to high androgen levels impairs neuronal development and induces autism-like behaviors in mice. Overexpression of the Nr4a2 gene or treatment with amodiaquine reverses these developmental abnormalities and behavioral deficits.
- Excessive prenatal dihydrotestosterone damages dendritic spine formation in offspring mice.
- Nr4a2 is identified as a key molecule mediating this androgen-induced neurodevelopmental impairment.
- Amodiaquine treatment significantly improves abnormal phenotypes caused by prenatal androgen exposure.
- This study links environmental hormonal factors to Nr4a2-dependent autism-like behaviors.
Gene Therapy for Parkinson's Disease Using Midbrain Developmental Genes to Regulate Dopaminergic Neuronal Maintenance.
Kim J, Chang MY
This review outlines how midbrain developmental genes like Nurr1 (NR4A2) and Foxa2 protect dopamine-producing neurons, suggesting that therapies targeting these pathways could slow disease progression in Parkinson's. It highlights that while current gene therapies focus on increasing dopamine levels, future strategies aim to maintain neuron integrity through neurotrophic factors and gene editing.
- Nurr1 and Foxa2 synergistically protect dopamine neurons from toxicity via paracrine signaling with glial cells.
- Current AAV-based dopamine replacement therapies show safety in early trials but do not slow disease progression.
- Disease-modifying strategies target neuron maintenance, neurotrophic factors like GDNF, and cellular stress pathways.
- Gene editing and delivery techniques are evolving to support more effective long-term treatments for Parkinson's.
Advanced paternal age exacerbates neuroinflammation in offspring via m6A modification-mediated intergenerational inheritance.
Mao Y, Meng Y, Zou K, Qin N, Wang Y, Yan J, Chen P, Cheng Y, Shi W, Zhou C, Chen H, Sheng J, Liu X, Pan J, Huang H
This mouse study shows that advanced paternal age causes neuroinflammation and behavioral issues in offspring by increasing a protein called Ythdc1, which suppresses the Nr4a2 gene. Suppressing Ythdc1 in these mice reduces inflammation and improves behavior, suggesting a potential therapeutic target for intergenerational epigenetic effects.
- Advanced paternal age causes cognitive impairment and autism-like behaviors in mouse offspring.
- Neuroinflammation results from microglial overactivation driven by increased Ythdc1 protein levels.
- Ythdc1 suppresses Nr4a2 expression, linking paternal aging to synaptic and immune dysfunction.
- Reducing Ythdc1 in the hippocampus alleviates behavioral abnormalities and neuroinflammation in affected mice.
Astragaloside IV Treats Parkinson's Disease by Regulating the Proliferation and Differentiation of NSCs through the SHH-Nurr1 Pathway.
Wu Z, Zhang J, Gao H, Li W
Astragaloside IV promotes the differentiation of neural stem cells into dopamine-producing neurons by activating the SHH-Nurr1 signaling pathway in preclinical models. This compound enhances cell activity and increases the expression of proteins essential for neuronal development through this specific molecular mechanism.
- Astragaloside IV stimulates neural stem cell proliferation and differentiation.
- The drug activates the SHH-Nurr1 signaling pathway to drive these effects.
- Nurr1 is a key transcription factor for dopamine neuron development.
- Results come from in vivo and in vitro experimental models.
- This study does not involve human patients or clinical trials.
Whole-genome sequencing identifies novel genes for autism in Chinese trios.
Chang S, Liu JJ, Zhao Y, Pang T, Zheng X, Song Z, Zhang A, Gao X, Luo L, Guo Y, Liu J, Yang L, Lu L
This study identifies NR4A2 as a potential risk gene for autism spectrum disorder through whole-genome sequencing of Chinese families. The findings support the link between NR4A2 variants and neurodevelopmental conditions, aligning with known clinical phenotypes.
- NR4A2 appears among high-confidence risk genes for autism in this genetic study.
- The research uses whole-genome sequencing on ASD patients and their parents.
- Results reinforce the association between NR4A2 and neurodevelopmental disorders.
- This is human genetic evidence relevant to NR4A2-related syndromes.
ASCL1-mediated direct reprogramming: converting ventral midbrain astrocytes into dopaminergic neurons for Parkinson's disease therapy.
Yong SH, Kim SM, Kong GW, Ko SH, Lee EH, Oh Y, Park CH
Researchers successfully convert midbrain astrocytes into dopaminergic neurons in a lab setting using specific transcription factors. This preclinical study demonstrates that ASCL1 alone can reprogram these cells, offering a potential future strategy for replacing lost neurons in Parkinson's disease.
- Lab study converts midbrain astrocytes into dopaminergic neurons using ASCL1.
- NURR1 and LMX1A are mentioned but ASCL1 alone suffices for reprogramming.
- Only ventral midbrain astrocytes respond, not cortical astrocytes.
- No human trials or clinical data involved in this research.
Development of Nurr1 agonists from amodiaquine by scaffold hopping and fragment growing.
Sai M, Hank EC, Tai HM, Kasch T, Lewandowski M, Vincendeau M, Marschner JA, Merk D
Researchers designed new chemical compounds that activate the Nurr1 protein with high potency. These compounds successfully restored key dopamine-related markers in human brain organoids carrying a Parkinson's disease mutation.
- New Nurr1 agonists show nanomolar potency and strong cellular target engagement.
- Compounds rescued tyrosine hydroxylase expression in LRRK2-mutated human midbrain organoids.
- Work provides chemical tools for validating Nurr1 as a therapeutic target.
Nurr1 overexpression in the primary motor cortex alleviates motor dysfunction induced by intracerebral hemorrhage in the striatum in mice.
Kinoshita K, Motomura K, Ushida K, Hirata Y, Konno A, Hirai H, Kotani S, Hitora-Imamura N, Kurauchi Y, Seki T, Katsuki H
Overexpressing Nurr1 in the motor cortex of mice with brain hemorrhage preserves nerve connections and improves movement, suggesting a potential mechanism for protecting motor pathways. This finding highlights how boosting Nurr1 activity might support motor function by maintaining axonal integrity rather than reducing inflammation at the injury site.
- Nurr1 overexpression in mouse motor cortex reduces motor deficits after brain hemorrhage.
- The treatment preserves corticospinal tract axons in the internal capsule.
- Mechanisms involve increased Ret kinase and Akt/ERK signaling in cortical neurons.
- No significant effect on inflammation, oxidative stress, or cell death in the striatum.
Reprogramming astrocytes into dopaminergic neurons to restore motor dysfunction in Parkinson's disease model rats.
Liu C, Ying M, Wang A, Liu Y, Chen Y, Ye W, Wen H, Ma C, Liu C, Guo Y
Researchers successfully converted rat brain support cells into dopamine-producing neurons using the NR4A2 (Nurr1) gene and transplanted them into Parkinson's disease model rats. The transplanted cells survived, integrated into the brain, and significantly improved motor function in the animals.
- NR4A2 combined with ASCL1 reprograms astrocytes into dopamine neurons in rats.
- Transplanted cells survive and express key dopamine markers like TH and FOXA2.
- Motor function improves significantly four to eight weeks after cell transplantation.
- This is a preclinical animal study, not human clinical evidence.
Unilateral rNurr1-V5 transgene expression in nigral dopaminergic neurons mitigates bilateral neuropathology and behavioral deficits in parkinsonian rats with α-synucleinopathy.
Gatica-Garcia B, Bannon MJ, Martínez-Dávila IA, Soto-Rojas LO, Reyes-Corona D, Escobedo L, Maldonado-Berny M, Gutierrez-Castillo ME, Espadas-Alvarez AJ, Fernandez-Parrilla MA, Mascotte-Cruz JU, Rodríguez-Oviedo CP, Valenzuela-Arzeta IE, Luna-Herrera C, Lopez-Salas FE, Santoyo-Salazar J, Martinez-Fong D
Introducing the Nurr1 gene into one side of the brain in rats with Parkinson-like symptoms reduces damage and improves movement on both sides. This suggests that boosting Nurr1 activity might protect dopamine neurons and reduce inflammation in neurodegenerative diseases.
- Unilateral Nurr1 gene delivery reduced bilateral nerve cell death in rat brains.
- Treatment lowered alpha-synuclein aggregates and neuroinflammation markers significantly.
- Rats showed improved sensorimotor behavior after the genetic intervention.
- The study uses a Parkinson's disease animal model, not human patients.
The role of Nurr1-miR-30e-5p-NLRP3 axis in inflammation-mediated neurodegeneration: insights from mouse models and patients' studies in Parkinson's disease.
Li T, Tan X, Tian L, Jia C, Cheng C, Chen X, Wei M, Wang Y, Hu Y, Jia Q, Ni Y, Al-Nusaif M, Li S, Le W
This study identifies a specific molecular pathway involving Nurr1, miR-30e-5p, and inflammation markers in Parkinson's disease patients. It confirms that reduced Nurr1 levels correlate with increased inflammatory activity in human blood cells, providing a potential biomarker for disease monitoring.
- Researchers analyzed blood samples from 450 Parkinson's patients and healthy controls.
- Nurr1 deficiency correlates with higher levels of inflammatory marker IL-1β in humans.
- The study maps a specific molecular axis linking Nurr1 to inflammation regulation.
- Mouse models confirm that Nurr1 loss triggers neurodegeneration via this inflammatory pathway.
Structure-Guided Design of Nurr1 Agonists Derived from the Natural Ligand Dihydroxyindole.
Sai M, Vietor J, Kornmayer M, Egner M, López-García Ú, Höfner G, Pabel J, Marschner JA, Wein T, Merk D
Researchers designed and tested new molecules that activate the Nurr1 protein, which is encoded by the NR4A2 gene. These compounds show strong binding affinity and work together to enhance target engagement in cell studies.
- New Nurr1 agonists derived from a natural dopamine metabolite are identified.
- Compounds demonstrate sub-micromolar binding affinity to the Nurr1 protein.
- Cellular tests confirm these molecules successfully engage the Nurr1 target.
- Combined treatment with multiple agonists shows additive effects on activation.
An optimized Nurr1 agonist provides disease-modifying effects in Parkinson's disease models.
Kim W, Tripathi M, Kim C, Vardhineni S, Cha Y, Kandi SK, Feitosa M, Kholiya R, Sah E, Thakur A, Kim Y, Ko S, Bhatia K, Manohar S, Kong YB, Sindhu G, Kim YS, Cohen B, Rawat DS, Kim KS
Researchers developed a new drug that activates the Nurr1 protein to protect dopamine neurons and improve symptoms in mouse models of Parkinson's disease. This compound shows promise for treating neurodegenerative conditions by preserving brain cells and restoring motor function without causing side effects like dyskinesia. While this work targets Parkinson's, it provides mechanistic insight into how activating NR4A2/Nurr1 might benefit dopaminergic systems.
- The drug activates Nurr1 to protect dopamine neurons in mouse models of Parkinson's disease.
- Treatment improved motor skills and olfactory deficits without causing dyskinesia-like behaviors.
- The compound is brain-penetrant and shows disease-modifying effects in preclinical studies.
- This research focuses on Parkinson's disease, not NR4A2-related neurodevelopmental syndromes.
Lithium's effects on therapeutic targets and MRI biomarkers in Parkinson's disease: A pilot clinical trial.
Guttuso T, Shepherd R, Frick L, Feltri ML, Frerichs V, Ramanathan M, Zivadinov R, Bergsland N
This pilot study shows that medium-dose lithium increases Nurr1 (NR4A2) expression in blood cells and improves MRI biomarkers associated with Parkinson's disease progression. However, the treatment was poorly tolerated, with one-third of participants withdrawing due to side effects. The findings suggest a potential biological mechanism but do not yet support clinical use for NR4A2-related syndromes.
- Medium-dose lithium significantly increased Nurr1 gene expression in patient blood cells.
- MRI scans showed reduced markers of brain decline in key motor and cognitive regions.
- Thirty-three percent of patients stopped treatment due to side effects.
- The study is a small pilot trial, not a definitive test of efficacy or safety.
Development of a Potent Nurr1 Agonist Tool for In Vivo Applications.
Vietor J, Gege C, Stiller T, Busch R, Schallmayer E, Kohlhof H, Höfner G, Pabel J, Marschner JA, Merk D
Researchers optimized a drug candidate to strongly activate Nurr1, the protein affected by NR4A2 mutations, showing it works in animal models. This compound serves as a precise tool for studying how Nurr1 activation might protect neurons, but it has not yet been tested in humans with NR4A2-related syndromes.
- The new compound activates Nurr1 with high potency and specificity over related receptors.
- It triggers protective gene expression in astrocytes in laboratory settings.
- Pharmacokinetics are favorable in rats, supporting further preclinical development.
- This is a chemical tool study, not a clinical trial for patients.
Genome-wide DNA methylation analysis in families with multiple individuals diagnosed with schizophrenia and intellectual disability.
Zhang S, Shi K, Lyu N, Zhang Y, Liang G, Zhang W, Wang X, Wen H, Wen L, Ma H, Wang J, Yu X, Guan L
This study identifies altered DNA methylation levels of the NR4A2 gene in families with schizophrenia and intellectual disability, suggesting epigenetic regulation contributes to these neurodevelopmental conditions. The findings highlight a potential link between NR4A2 expression changes and disease development, though they do not establish causality or therapeutic targets for NR4A2 syndrome.
- Study analyzes DNA methylation in monozygotic twin families with schizophrenia or intellectual disability.
- Altered methylation of NR4A2 associates with the development of schizophrenia and intellectual disability.
- Results suggest neurodevelopment and immune system pathways are involved in these disorders.
- Research focuses on epigenetic mechanisms rather than genetic mutations or clinical outcomes.